Non Hodgkin Lymphoma Clinical Trial

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Summary

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders.

II. To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs. (Completed) III. To determine the objective response rates (ORR; complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents.

SECONDARY OBJECTIVES:

I. To estimate the progression free survival in pediatric patients receiving targeted therapies for advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders.

II. To obtain preliminary or additional information about the tolerability of targeted therapies in children with advanced cancers.

III. To provide preliminary estimates of the pharmacokinetics of targeted therapies in children with advanced cancers.

IV. To obtain preliminary information on the response rate to targeted therapy in patients whose tumors lack actionable alterations as defined for the molecular analysis for therapy choice (MATCH) study, for selected agents for which efficacy is observed in the primary matched cohort.

EXPLORATORY OBJECTIVES:

I. To increase knowledge of the genomic landscape of advanced pediatric solid tumors, non-Hodgkin lymphomas, and histiocytic disorders.

II. To describe the genomic changes that occur in advanced pediatric cancers between the time of initial diagnosis and relapse, in cases for which paired tumor specimens are available.

III. To explore approaches to diagnosing and profiling genomics of advanced pediatric cancers through evaluation of circulating tumor deoxyribonucleic acid (DNA).

IV. To determine the frequency and spectrum of germline cancer susceptibility mutations in children with relapsed solid tumors and non-Hodgkin lymphomas and assess the feasibility of return of those results in the National Clinical Trial Network (NCTN) group setting.

OUTLINE:

STEP 1 (SCREENING): Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.

STEP 2 (TREATMENT): Patients with a mutation targeted by one or more of the investigational drugs used in this study or those without mutations are assigned to 1 of 10 treatment subprotocols.

APEC1621A: Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib sulfate orally (PO) or via nasogastric- or gastric-tube twice daily (BID) on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621B: Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive erdafitinib PO once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, computed tomography (CT scan), magnetic resonance imaging (MRI), radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.

APEC1621C: Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621D: Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621E: Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621F: Patients with an ALK or ROS1 gene alteration receive ensartinib (ALK Inhibitor X-396) PO BID on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.

APEC1621G: Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621H: Patients with deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621I: Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621J: Patients with MAPK Pathway Mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

APEC1621M: Patients with HRAS gene alterations receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.

APEC1621N: Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.

After completion of study treatment, patients are followed up periodically.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment
ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients with recurrent or refractory solid tumors, including non-Hodgkin lymphomas, histiocytoses (e.g. langerhans cell histiocytosis [LCH], juvenile xanthogranuloma [JXG], histiocytic sarcoma), and central nervous system (CNS) tumors are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG); in cases where patient enrolls prior to histologic confirmation of recurrent disease, patient is ineligible and should be withdrawn from study if histology fails to confirm recurrence; please note: Patients with Hodgkin lymphoma and plexiform neurofibroma are not eligible

ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Tumor Testing Requirement: Tumor sample availability requirement for stage 1 of Pediatric MATCH (patients enrolled from start of study in July 2017 through 12/31/21); Patients must have an formalin-fixed paraffin-embedded (FFPE) tumor sample available for MATCH study testing from a biopsy or surgery that was performed at any point after initial tumor recurrence/progression, or be planned to have a procedure to obtain such a sample that is considered to be of potential benefit by the treating clinicians; a tumor sample from a clinically performed diagnostic (pre-treatment) biopsy will be acceptable for enrollment onto Pediatric MATCH only for children with high-grade gliomas of the brainstem (diffuse intrinsic pontine gliomas) or thalamus

Please note: Samples that have been decalcified using standardly utilized acid-based decalcification methods are not generally suitable for MATCH study testing; the nucleic acids will have been degraded in the decalcification process

ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Tumor molecular profiling report availability requirement for Stage 2 of Pediatric MATCH (patients enrolled starting 2022): In stage 2 of the study, no tumor samples will be submitted for centralized clinical tumor profiling; instead, a tumor molecular profiling report from a College of American Pathologists (CAP)/ Clinical Laboratory Improvements Amendments (CLIA)-approved testing laboratory must be submitted for review by the Molecular Review Committee (MRC)

This molecular profiling must have been performed on a tumor sample that was obtained at any point after initial tumor recurrence/progression and must be accompanied by a pathology report for the same tumor specimen; a molecular profiling report for a diagnostic (pre-treatment) tumor sample will be acceptable for enrollment onto Pediatric MATCH only for children with high-grade gliomas of the brainstem (diffuse intrinsic pontine gliomas) or thalamus. In the event that molecular profiling reports are available from multiple timepoints, the most recent report should be prioritized for study submission
ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age); note: neurologic deficits in patients with central nervous system (CNS) tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score

ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must have radiographically measurable disease; measurable disease based on imaging obtained less than or equal to 56 days prior to enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard magnetic resonance imaging (MRI) or computed tomography (CT)

Note: The following do not qualify as measurable disease:

Malignant fluid collections (e.g., ascites, pleural effusions)
Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma
Elevated tumor markers in plasma or CSF
Previously radiated lesions that have not demonstrated clear progression post radiation
Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: NOTE: patient does not need to meet all subprotocol criteria at time of enrollment onto the APEC1621SC screening protocol, but will need to meet all criteria prior to enrollment on any assigned treatment subprotocol. Patients must be enrolled onto a subprotocol within 2 weeks (14 days) of treatment assignment
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age); Note: neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score

GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol specified therapy, the patients must have radiographically measurable disease; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard MRI or CT

Note: The following do not qualify as measurable disease:

Malignant fluid collections (e.g., ascites, pleural effusions)
Bone marrow infiltration except that detected by MIBG scan for neuroblastoma
Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma
Elevated tumor markers in plasma or CSF
Previously radiated lesions that have not demonstrated clear progression post radiation
Leptomeningeal lesions that do not meet the measurement requirements for RECIST 1.1

GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of enrollment onto a subprotocol, the following general criteria for initiation of therapy will be required:

Patients must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer directed therapy prior to enrollment to the subprotocol; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately

Cytotoxic chemotherapy or other anticancer agents known to be myelosuppressive: for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
Anticancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil counts [ANC]): >= 7 days after the last dose of agent; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment
Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator
Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)

Stem cell infusions (with or without total-body irradiation [TBI]):

Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)
Autologous stem cell infusion including boost infusion: >= 42 days
Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer (NK) cells, dendritic cells, etc.)
X-ray therapy (XRT)/External Beam Irradiation including Protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation; note: radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radiopharmaceutical therapy

GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:

Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity

GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6
Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8
Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1
Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2
Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4
Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Serum glutamate pyruvate transaminase (SGPT) (alanine transferase [ALT]) =< 135 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Agent specific limitations on prior therapy will be included with specific treatment subprotocols

Exclusion Criteria:

GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies, or because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in females who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method

GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications

Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
Investigational drugs: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol
Anticancer agents: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol
Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have an uncontrolled infection are not eligible
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have had a prior solid organ transplant are not eligible
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Additional agent specific criteria will be included with specific treatment subprotocols

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

2316

Study ID:

NCT03155620

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 163 Locations for this study

See Locations Near You

Children's Hospital of Alabama
Birmingham Alabama, 35233, United States More Info
Site Public Contact
Contact
205-638-9285
[email protected]
Elizabeth D. Alva
Principal Investigator
Providence Alaska Medical Center
Anchorage Alaska, 99508, United States More Info
Site Public Contact
Contact
907-212-6871
[email protected]
Brenda J. Wittman
Principal Investigator
Banner Children's at Desert
Mesa Arizona, 85202, United States More Info
Site Public Contact
Contact
480-412-3100
Joseph C. Torkildson
Principal Investigator
Phoenix Childrens Hospital
Phoenix Arizona, 85016, United States More Info
Site Public Contact
Contact
602-546-0920
Alok K. Kothari
Principal Investigator
Banner University Medical Center - Tucson
Tucson Arizona, 85719, United States More Info
Site Public Contact
Contact
[email protected]
Holly E. Pariury
Principal Investigator
Arkansas Children's Hospital
Little Rock Arkansas, 72202, United States More Info
Site Public Contact
Contact
501-364-7373
David L. Becton
Principal Investigator
Kaiser Permanente Downey Medical Center
Downey California, 90242, United States More Info
Site Public Contact
Contact
626-564-3455
Robert M. Cooper
Principal Investigator
City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States More Info
Site Public Contact
Contact
800-826-4673
[email protected]
Janet M. Yoon
Principal Investigator
Loma Linda University Medical Center
Loma Linda California, 92354, United States More Info
Site Public Contact
Contact
909-558-4050
Albert Kheradpour
Principal Investigator
Miller Children's and Women's Hospital Long Beach
Long Beach California, 90806, United States More Info
Site Public Contact
Contact
562-933-5600
Jacqueline N. Casillas
Principal Investigator
Children's Hospital Los Angeles
Los Angeles California, 90027, United States More Info
Site Public Contact
Contact
323-361-4110
Fariba Navid
Principal Investigator
Cedars Sinai Medical Center
Los Angeles California, 90048, United States More Info
Site Public Contact
Contact
310-423-8965
Fataneh (Fae) Majlessipour
Principal Investigator
Mattel Children's Hospital UCLA
Los Angeles California, 90095, United States More Info
Site Public Contact
Contact
310-825-6708
Theodore B. Moore
Principal Investigator
Valley Children's Hospital
Madera California, 93636, United States More Info
Site Public Contact
Contact
559-353-3000
[email protected]
Karen S. Fernandez
Principal Investigator
UCSF Benioff Children's Hospital Oakland
Oakland California, 94609, United States More Info
Site Public Contact
Contact
510-428-3324
[email protected]
Carla B. Golden
Principal Investigator
Kaiser Permanente-Oakland
Oakland California, 94611, United States More Info
Site Public Contact
Contact
877-642-4691
[email protected]
Aarati V. Rao
Principal Investigator
Children's Hospital of Orange County
Orange California, 92868, United States More Info
Site Public Contact
Contact
714-509-8646
[email protected]
Elyssa M. Rubin
Principal Investigator
Lucile Packard Children's Hospital Stanford University
Palo Alto California, 94304, United States More Info
Site Public Contact
Contact
800-694-0012
[email protected]
Jay Michael S. Balagtas
Principal Investigator
University of California Davis Comprehensive Cancer Center
Sacramento California, 95817, United States More Info
Site Public Contact
Contact
916-734-3089
Marcio H. Malogolowkin
Principal Investigator
Rady Children's Hospital - San Diego
San Diego California, 92123, United States More Info
Site Public Contact
Contact
858-966-5934
William D. Roberts
Principal Investigator
Naval Medical Center -San Diego
San Diego California, 92134, United States More Info
Site Public Contact
Contact
619-532-8712
Yoko T. Udaka
Principal Investigator
UCSF Medical Center-Mission Bay
San Francisco California, 94158, United States More Info
Site Public Contact
Contact
877-827-3222
[email protected]
Arun A. Rangaswami
Principal Investigator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance California, 90502, United States More Info
Site Public Contact
Contact
310-222-3624
[email protected]
Eduard H. Panosyan
Principal Investigator
Children's Hospital Colorado
Aurora Colorado, 80045, United States More Info
Site Public Contact
Contact
303-764-5056
[email protected]
Margaret E. Macy
Principal Investigator
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver Colorado, 80218, United States More Info
Site Public Contact
Contact
303-839-6000
Jennifer J. Clark
Principal Investigator
Connecticut Children's Medical Center
Hartford Connecticut, 06106, United States More Info
Site Public Contact
Contact
860-545-9981
Michael S. Isakoff
Principal Investigator
Yale University
New Haven Connecticut, 06520, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Farzana Pashankar
Principal Investigator
Alfred I duPont Hospital for Children
Wilmington Delaware, 19803, United States More Info
Site Public Contact
Contact
302-651-5572
[email protected]
Scott M. Bradfield
Principal Investigator
MedStar Georgetown University Hospital
Washington District of Columbia, 20007, United States More Info
Site Public Contact
Contact
202-444-2223
Nina S. Kadan-Lottick
Principal Investigator
Children's National Medical Center
Washington District of Columbia, 20010, United States More Info
Site Public Contact
Contact
202-884-2549
Jeffrey S. Dome
Principal Investigator
Broward Health Medical Center
Fort Lauderdale Florida, 33316, United States More Info
Site Public Contact
Contact
302-651-5572
[email protected]
Hector M. Rodriguez-Cortes
Principal Investigator
Golisano Children's Hospital of Southwest Florida
Fort Myers Florida, 33908, United States More Info
Site Public Contact
Contact
239-343-5333
[email protected]
Emad K. Salman
Principal Investigator
University of Florida Health Science Center - Gainesville
Gainesville Florida, 32610, United States More Info
Site Public Contact
Contact
352-273-8010
[email protected]
William B. Slayton
Principal Investigator
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood Florida, 33021, United States More Info
Site Public Contact
Contact
954-265-1847
[email protected]
Iftikhar Hanif
Principal Investigator
Nemours Children's Clinic-Jacksonville
Jacksonville Florida, 32207, United States More Info
Site Public Contact
Contact
302-651-5572
[email protected]
Scott M. Bradfield
Principal Investigator
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami Florida, 33136, United States More Info
Site Public Contact
Contact
305-243-2647
Julio C. Barredo
Principal Investigator
Nicklaus Children's Hospital
Miami Florida, 33155, United States More Info
Site Public Contact
Contact
888-624-2778
Ziad A. Khatib
Principal Investigator
AdventHealth Orlando
Orlando Florida, 32803, United States
Arnold Palmer Hospital for Children
Orlando Florida, 32806, United States More Info
Site Public Contact
Contact
321-841-5357
[email protected]
Amy A. Smith
Principal Investigator
Nemours Children's Hospital
Orlando Florida, 32827, United States More Info
Site Public Contact
Contact
302-651-5572
[email protected]
Scott M. Bradfield
Principal Investigator
Nemours Children's Clinic - Pensacola
Pensacola Florida, 32504, United States
Sacred Heart Hospital
Pensacola Florida, 32504, United States More Info
Site Public Contact
Contact
850-416-4611
[email protected]
Erlyn C. Smith
Principal Investigator
Johns Hopkins All Children's Hospital
Saint Petersburg Florida, 33701, United States More Info
Site Public Contact
Contact
727-767-4784
[email protected]
Stacie L. Stapleton
Principal Investigator
Tampa General Hospital
Tampa Florida, 33606, United States More Info
Site Public Contact
Contact
813-844-7829
[email protected]
Juan F. Rico
Principal Investigator
Saint Joseph's Hospital/Children's Hospital-Tampa
Tampa Florida, 33607, United States
Saint Mary's Hospital
West Palm Beach Florida, 33407, United States More Info
Site Public Contact
Contact
561-881-2815
Narayana Gowda
Principal Investigator
Children's Healthcare of Atlanta - Egleston
Atlanta Georgia, 30322, United States More Info
Site Public Contact
Contact
404-785-2025
[email protected]
William T. Cash
Principal Investigator
Memorial Health University Medical Center
Savannah Georgia, 31404, United States More Info
Site Public Contact
Contact
912-350-7887
[email protected]
Andrew L. Pendleton
Principal Investigator
Kapiolani Medical Center for Women and Children
Honolulu Hawaii, 96826, United States More Info
Site Public Contact
Contact
808-983-6090
Wade T. Kyono
Principal Investigator
Saint Luke's Cancer Institute - Boise
Boise Idaho, 83712, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Eugenia Chang
Principal Investigator
Lurie Children's Hospital-Chicago
Chicago Illinois, 60611, United States More Info
Site Public Contact
Contact
773-880-4562
David O. Walterhouse
Principal Investigator
University of Illinois
Chicago Illinois, 60612, United States More Info
Site Public Contact
Contact
312-355-3046
Mary L. Schmidt
Principal Investigator
University of Chicago Comprehensive Cancer Center
Chicago Illinois, 60637, United States More Info
Site Public Contact
Contact
773-702-8222
[email protected]
Susan L. Cohn
Principal Investigator
Loyola University Medical Center
Maywood Illinois, 60153, United States More Info
Site Public Contact
Contact
708-226-4357
Eugene Suh
Principal Investigator
Saint Jude Midwest Affiliate
Peoria Illinois, 61637, United States More Info
Site Public Contact
Contact
888-226-4343
Jaime M. Libes
Principal Investigator
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Gregory P. Brandt
Principal Investigator
Riley Hospital for Children
Indianapolis Indiana, 46202, United States More Info
Site Public Contact
Contact
800-248-1199
Sandeep Batra
Principal Investigator
Ascension Saint Vincent Indianapolis Hospital
Indianapolis Indiana, 46260, United States More Info
Site Public Contact
Contact
317-338-2194
[email protected]
Bassem I. Razzouk
Principal Investigator
Blank Children's Hospital
Des Moines Iowa, 50309, United States More Info
Site Public Contact
Contact
515-241-8912
[email protected]
Samantha L. Mallory
Principal Investigator
University of Iowa/Holden Comprehensive Cancer Center
Iowa City Iowa, 52242, United States More Info
Site Public Contact
Contact
800-237-1225
David S. Dickens
Principal Investigator
University of Kentucky/Markey Cancer Center
Lexington Kentucky, 40536, United States More Info
Site Public Contact
Contact
859-257-3379
James T. Badgett
Principal Investigator
Norton Children's Hospital
Louisville Kentucky, 40202, United States More Info
Site Public Contact
Contact
502-629-5500
[email protected]
Ashok B. Raj
Principal Investigator
Children's Hospital New Orleans
New Orleans Louisiana, 70118, United States More Info
Site Public Contact
Contact
[email protected]
Lolie C. Yu
Principal Investigator
Ochsner Medical Center Jefferson
New Orleans Louisiana, 70121, United States More Info
Site Public Contact
Contact
504-842-8084
[email protected]
Craig Lotterman
Principal Investigator
Eastern Maine Medical Center
Bangor Maine, 04401, United States More Info
Site Public Contact
Contact
207-973-4274
Nadine P. SantaCruz
Principal Investigator
Maine Children's Cancer Program
Scarborough Maine, 04074, United States More Info
Site Public Contact
Contact
207-396-7581
[email protected]
Eric C. Larsen
Principal Investigator
University of Maryland/Greenebaum Cancer Center
Baltimore Maryland, 21201, United States More Info
Site Public Contact
Contact
800-888-8823
Teresa A. York
Principal Investigator
Sinai Hospital of Baltimore
Baltimore Maryland, 21215, United States More Info
Site Public Contact
Contact
410-601-6120
[email protected]
Jason M. Fixler
Principal Investigator
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore Maryland, 21287, United States More Info
Site Public Contact
Contact
410-955-8804
[email protected]
Kenneth J. Cohen
Principal Investigator
National Institutes of Health Clinical Center
Bethesda Maryland, 20892, United States
Massachusetts General Hospital Cancer Center
Boston Massachusetts, 02114, United States More Info
Site Public Contact
Contact
877-726-5130
Katherine A. Janeway
Principal Investigator
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Site Public Contact
Contact
877-442-3324
Katherine A. Janeway
Principal Investigator
UMass Memorial Medical Center - University Campus
Worcester Massachusetts, 01655, United States More Info
Site Public Contact
Contact
508-856-3216
[email protected]
Stefanie R. Lowas
Principal Investigator
C S Mott Children's Hospital
Ann Arbor Michigan, 48109, United States More Info
Site Public Contact
Contact
800-865-1125
Rajen Mody
Principal Investigator
Wayne State University/Karmanos Cancer Institute
Detroit Michigan, 48201, United States More Info
Site Public Contact
Contact
313-576-9790
[email protected]
Jeffrey W. Taub
Principal Investigator
Michigan State University Clinical Center
East Lansing Michigan, 48824, United States More Info
Site Public Contact
Contact
517-975-9547
Laura E. Agresta
Principal Investigator
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids Michigan, 49503, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Bronson Methodist Hospital
Kalamazoo Michigan, 49007, United States More Info
Site Public Contact
Contact
616-391-1230
[email protected]
Kathleen J. Yost
Principal Investigator
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis Minnesota, 55404, United States More Info
Site Public Contact
Contact
612-813-5193
Michael K. Richards
Principal Investigator
University of Minnesota/Masonic Cancer Center
Minneapolis Minnesota, 55455, United States More Info
Site Public Contact
Contact
612-624-2620
Emily G. Greengard
Principal Investigator
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Site Public Contact
Contact
855-776-0015
Carola A. Arndt
Principal Investigator
University of Mississippi Medical Center
Jackson Mississippi, 39216, United States More Info
Site Public Contact
Contact
601-815-6700
Anderson (Andy) B. Collier
Principal Investigator
Children's Mercy Hospitals and Clinics
Kansas City Missouri, 64108, United States More Info
Site Public Contact
Contact
816-302-6808
[email protected]
Kevin F. Ginn
Principal Investigator
Cardinal Glennon Children's Medical Center
Saint Louis Missouri, 63104, United States More Info
Site Public Contact
Contact
314-268-4000
William S. Ferguson
Principal Investigator
Washington University School of Medicine
Saint Louis Missouri, 63110, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Robert J. Hayashi
Principal Investigator
Mercy Hospital Saint Louis
Saint Louis Missouri, 63141, United States More Info
Site Public Contact
Contact
314-251-7066
Robin D. Hanson
Principal Investigator
Children's Hospital and Medical Center of Omaha
Omaha Nebraska, 68114, United States More Info
Site Public Contact
Contact
402-955-3949
Jill C. Beck
Principal Investigator
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States More Info
Site Public Contact
Contact
402-559-6941
[email protected]
Jill C. Beck
Principal Investigator
University Medical Center of Southern Nevada
Las Vegas Nevada, 89102, United States
Sunrise Hospital and Medical Center
Las Vegas Nevada, 89109, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
Alan K. Ikeda
Principal Investigator
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas Nevada, 89135, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
Alan K. Ikeda
Principal Investigator
Summerlin Hospital Medical Center
Las Vegas Nevada, 89144, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
Alan K. Ikeda
Principal Investigator
Dartmouth Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States More Info
Site Public Contact
Contact
800-639-6918
[email protected]
Julie Kim
Principal Investigator
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Site Public Contact
Contact
201-996-2879
Katharine Offer
Principal Investigator
Morristown Medical Center
Morristown New Jersey, 07960, United States More Info
Site Public Contact
Contact
973-971-5900
Kathryn L. Laurie
Principal Investigator
Saint Peter's University Hospital
New Brunswick New Jersey, 08901, United States More Info
Site Public Contact
Contact
732-745-8600
[email protected]
Nibal A. Zaghloul
Principal Investigator
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick New Jersey, 08903, United States More Info
Site Public Contact
Contact
732-235-8675
Richard A. Drachtman
Principal Investigator
Albany Medical Center
Albany New York, 12208, United States More Info
Site Public Contact
Contact
518-262-5513
Lauren R. Weintraub
Principal Investigator
Roswell Park Cancer Institute
Buffalo New York, 14263, United States More Info
Site Public Contact
Contact
800-767-9355
[email protected]
Clare J. Twist
Principal Investigator
NYU Winthrop Hospital
Mineola New York, 11501, United States More Info
Site Public Contact
Contact
212-263-4432
[email protected]
Chana L. Glasser
Principal Investigator
The Steven and Alexandra Cohen Children's Medical Center of New York
New Hyde Park New York, 11040, United States More Info
Site Public Contact
Contact
718-470-3460
Julie I. Krystal
Principal Investigator
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York New York, 10016, United States More Info
Site Public Contact
Contact
[email protected]
Sharon L. Gardner
Principal Investigator
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York New York, 10032, United States More Info
Site Public Contact
Contact
212-305-6361
[email protected]
Justine M. Kahn
Principal Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Site Public Contact
Contact
212-639-7592
Tara O'Donohue
Principal Investigator
NYP/Weill Cornell Medical Center
New York New York, 10065, United States More Info
Site Public Contact
Contact
212-746-1848
Alexander J. Chou
Principal Investigator
University of Rochester
Rochester New York, 14642, United States More Info
Site Public Contact
Contact
585-275-5830
Craig A. Mullen
Principal Investigator
Stony Brook University Medical Center
Stony Brook New York, 11794, United States More Info
Site Public Contact
Contact
800-862-2215
Laura E. Hogan
Principal Investigator
State University of New York Upstate Medical University
Syracuse New York, 13210, United States More Info
Site Public Contact
Contact
315-464-5476
Philip M. Monteleone
Principal Investigator
New York Medical College
Valhalla New York, 10595, United States More Info
Site Public Contact
Contact
914-594-3794
Jessica C. Hochberg
Principal Investigator
Mission Hospital
Asheville North Carolina, 28801, United States More Info
Site Public Contact
Contact
828-213-7055
[email protected]
Douglas J. Scothorn
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina, 27599, United States More Info
Site Public Contact
Contact
877-668-0683
[email protected]
Stuart H. Gold
Principal Investigator
Carolinas Medical Center/Levine Cancer Institute
Charlotte North Carolina, 28203, United States More Info
Site Public Contact
Contact
800-804-9376
Joel A. Kaplan
Principal Investigator
Novant Health Presbyterian Medical Center
Charlotte North Carolina, 28204, United States
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Site Public Contact
Contact
888-275-3853
Lars M. Wagner
Principal Investigator
East Carolina University
Greenville North Carolina, 27834, United States More Info
Site Public Contact
Contact
252-744-1015
[email protected]
Andrea R. Whitfield
Principal Investigator
Wake Forest University Health Sciences
Winston-Salem North Carolina, 27157, United States More Info
Site Public Contact
Contact
336-713-6771
Thomas W. McLean
Principal Investigator
Children's Hospital Medical Center of Akron
Akron Ohio, 44308, United States More Info
Site Public Contact
Contact
330-543-3193
Erin Wright
Principal Investigator
Cincinnati Children's Hospital Medical Center
Cincinnati Ohio, 45229, United States More Info
Site Public Contact
Contact
513-636-2799
[email protected]
Erin H. Breese
Principal Investigator
Rainbow Babies and Childrens Hospital
Cleveland Ohio, 44106, United States More Info
Site Public Contact
Contact
216-844-5437
Duncan S. Stearns
Principal Investigator
Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States More Info
Site Public Contact
Contact
866-223-8100
[email protected]
Rabi Hanna
Principal Investigator
Nationwide Children's Hospital
Columbus Ohio, 43205, United States More Info
Site Public Contact
Contact
614-722-6039
[email protected]
Mark A. Ranalli
Principal Investigator
Dayton Children's Hospital
Dayton Ohio, 45404, United States More Info
Site Public Contact
Contact
800-228-4055
Mukund G. Dole
Principal Investigator
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo Ohio, 43606, United States More Info
Site Public Contact
Contact
419-824-1842
[email protected]
Jamie L. Dargart
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Rene Y. McNall-Knapp
Principal Investigator
Legacy Emanuel Children's Hospital
Portland Oregon, 97227, United States More Info
Site Public Contact
Contact
503-413-2560
Janice F. Olson
Principal Investigator
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Site Public Contact
Contact
503-494-1080
[email protected]
Katrina Winsnes
Principal Investigator
Lehigh Valley Hospital-Cedar Crest
Allentown Pennsylvania, 18103, United States More Info
Site Public Contact
Contact
610-402-9543
[email protected]
Jacob A. Troutman
Principal Investigator
Geisinger Medical Center
Danville Pennsylvania, 17822, United States More Info
Site Public Contact
Contact
570-271-5251
[email protected]
Jagadeesh Ramdas
Principal Investigator
Children's Hospital of Philadelphia
Philadelphia Pennsylvania, 19104, United States More Info
Site Public Contact
Contact
267-425-5544
[email protected]
Frank M. Balis
Principal Investigator
Children's Hospital of Pittsburgh of UPMC
Pittsburgh Pennsylvania, 15224, United States More Info
Site Public Contact
Contact
412-692-8570
[email protected]
Jean M. Tersak
Principal Investigator
Rhode Island Hospital
Providence Rhode Island, 02903, United States More Info
Site Public Contact
Contact
401-444-1488
Jennifer J. Welch
Principal Investigator
Prisma Health Richland Hospital
Columbia South Carolina, 29203, United States More Info
Site Public Contact
Contact
864-241-6251
Stuart L. Cramer
Principal Investigator
BI-LO Charities Children's Cancer Center
Greenville South Carolina, 29605, United States More Info
Site Public Contact
Contact
864-241-6251
Aniket Saha
Principal Investigator
Sanford USD Medical Center - Sioux Falls
Sioux Falls South Dakota, 57117, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Kayelyn J. Wagner
Principal Investigator
East Tennessee Childrens Hospital
Knoxville Tennessee, 37916, United States More Info
Site Public Contact
Contact
865-541-8266
Susan E. Spiller
Principal Investigator
Saint Jude Children's Research Hospital
Memphis Tennessee, 38105, United States More Info
Site Public Contact
Contact
888-226-4343
[email protected]
Alberto S. Pappo
Principal Investigator
The Children's Hospital at TriStar Centennial
Nashville Tennessee, 37203, United States More Info
Site Public Contact
Contact
615-342-1919
Jennifer A. Domm
Principal Investigator
Vanderbilt University/Ingram Cancer Center
Nashville Tennessee, 37232, United States More Info
Site Public Contact
Contact
800-811-8480
Scott C. Borinstein
Principal Investigator
Dell Children's Medical Center of Central Texas
Austin Texas, 78723, United States More Info
Site Public Contact
Contact
512-628-1902
[email protected]
Shannon M. Cohn
Principal Investigator
Driscoll Children's Hospital
Corpus Christi Texas, 78411, United States More Info
Site Public Contact
Contact
361-694-5311
[email protected]
Nkechi I. Mba
Principal Investigator
Medical City Dallas Hospital
Dallas Texas, 75230, United States More Info
Site Public Contact
Contact
972-566-5588
Stanton C. Goldman
Principal Investigator
UT Southwestern/Simmons Cancer Center-Dallas
Dallas Texas, 75390, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Avanthi T. Shah
Principal Investigator
El Paso Children's Hospital
El Paso Texas, 79905, United States More Info
Site Public Contact
Contact
915-298-5444
[email protected]
Ranjan Bista
Principal Investigator
Cook Children's Medical Center
Fort Worth Texas, 76104, United States More Info
Site Public Contact
Contact
682-885-2103
[email protected]
Kelly L. Vallance
Principal Investigator
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston Texas, 77030, United States More Info
Site Public Contact
Contact
713-798-1354
[email protected]
Jennifer H. Foster
Principal Investigator
M D Anderson Cancer Center
Houston Texas, 77030, United States More Info
Site Public Contact
Contact
877-632-6789
[email protected]
Najat C. Daw
Principal Investigator
Covenant Children's Hospital
Lubbock Texas, 79410, United States More Info
Site Public Contact
Contact
[email protected]
Kishor M. Bhende
Principal Investigator
UMC Cancer Center / UMC Health System
Lubbock Texas, 79415, United States More Info
Site Public Contact
Contact
806-775-8590
Erin K. Barr
Principal Investigator
Children's Hospital of San Antonio
San Antonio Texas, 78207, United States More Info
Site Public Contact
Contact
210-704-2894
[email protected]
Timothy C. Griffin
Principal Investigator
Methodist Children's Hospital of South Texas
San Antonio Texas, 78229, United States More Info
Site Public Contact
Contact
210-575-6240
[email protected]
Jose M. Esquilin
Principal Investigator
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States More Info
Site Public Contact
Contact
210-450-3800
[email protected]
Anne-Marie R. Langevin
Principal Investigator
Scott and White Memorial Hospital
Temple Texas, 76508, United States More Info
Site Public Contact
Contact
254-724-5407
Nicholas W. McGregor
Principal Investigator
Primary Children's Hospital
Salt Lake City Utah, 84113, United States More Info
Site Public Contact
Contact
801-585-5270
Matthew Dietz
Principal Investigator
University of Vermont and State Agricultural College
Burlington Vermont, 05405, United States More Info
Site Public Contact
Contact
802-656-8990
[email protected]
Jessica L. Heath
Principal Investigator
Children's Hospital of The King's Daughters
Norfolk Virginia, 23507, United States More Info
Site Public Contact
Contact
757-668-7243
[email protected]
Eric J. Lowe
Principal Investigator
Naval Medical Center - Portsmouth
Portsmouth Virginia, 23708, United States More Info
Site Public Contact
Contact
757-953-5939
Bethany M. Mikles
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
Gita V. Massey
Principal Investigator
Seattle Children's Hospital
Seattle Washington, 98105, United States More Info
Site Public Contact
Contact
866-987-2000
Sarah E. Leary
Principal Investigator
Providence Sacred Heart Medical Center and Children's Hospital
Spokane Washington, 99204, United States More Info
Site Public Contact
Contact
800-228-6618
[email protected]
Judy L. Felgenhauer
Principal Investigator
Mary Bridge Children's Hospital and Health Center
Tacoma Washington, 98405, United States More Info
Site Public Contact
Contact
253-403-1461
[email protected]
Robert G. Irwin
Principal Investigator
Madigan Army Medical Center
Tacoma Washington, 98431, United States More Info
Site Public Contact
Contact
253-968-6144
[email protected]
Melissa A. Forouhar
Principal Investigator
West Virginia University Healthcare
Morgantown West Virginia, 26506, United States
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Site Public Contact
Contact
800-622-8922
Kenneth B. De Santes
Principal Investigator
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Michelle A. Manalang
Principal Investigator
Children's Hospital of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Site Public Contact
Contact
414-955-4727
[email protected]
Paul D. Harker-Murray
Principal Investigator
San Jorge Children's Hospital
San Juan , 00912, Puerto Rico
University Pediatric Hospital
San Juan , 00926, Puerto Rico More Info
Site Public Contact
Contact
787-474-0333
Maria E. Echevarria
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

2316

Study ID:

NCT03155620

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.